Stocks of Xeris Biopharma Holdings Inc (NASDAQ:XERS) traded higher last session on Wall Street, down -1.40% to $5.63.
XERS stock price is now 38.04% away from the 50-day moving average and 78.15% away from the 200-day moving average. The market capitalization of the company currently stands at $866.68M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $3, Piper Sandler recently Downgraded its rating from Overweight to Neutral for Xeris Biopharma Holdings Inc (NASDAQ: XERS). On March 28, 2024, Oppenheimer recently initiated its ‘Outperform’ rating on the stock quoting a target price of $5, while ‘Craig Hallum’ rates the stock as ‘Buy’
In other news, Hecht Beth, insider sold 40,000 shares of the company’s stock on Mar 20 ’25. The stock was sold for $217,244 at an average price of $5.43. Upon completion of the transaction, the insider now directly owns 1,353,510 shares in the company, valued at $7.62 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 20 ’25, Officer Hecht Beth bought 40,000 shares of the business’s stock. A total of $205,600 was incurred on buying the stock at an average price of $5.14. A total of 7.76% of the company’s stock is owned by insiders.
During the past 12 months, Xeris Biopharma Holdings Inc has had a low of $1.69 and a high of $6.07. The fifty day moving average price for XERS is $4.0786 and a two-hundred day moving average price translates $3.1603 for the stock.
The latest earnings results from Xeris Biopharma Holdings Inc (NASDAQ: XERS) was released for 2024-12-31. The net profit margin was -27.00% and return on equity was -617.16% for XERS. The company reported revenue of $60.1 million for the quarter, compared to $44.39 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 35.39 percent.
